DPP-4 INHIBITION ATTENUATES CARDIAC DYSFUNCTION AND ADVERSE REMODELLING FOLLOWING MYOCARDIAL INFARCTION IN EXPERIMENTAL DIABETES

被引：1
|
作者：
Connelly, K. A.
Desjardins, J.
Advani, A.
Kabir, G.
Zhang, Y.
Advani, S. L.
Yuen, D. A.
Thai, K.
Gilbert, R. E.
机构：
来源：
CANADIAN JOURNAL OF CARDIOLOGY | 2011年 / 27卷 / 05期
关键词：
D O I：
10.1016/j.cjca.2011.07.597
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S328 / S328
页数：1
相关论文
共 50 条
  • [31] DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction
    Seung Jung Kim
    Soon Kil Kwon
    Hye-Young Kim
    Sun Moon Kim
    Jang-Whan Bae
    Joong-Kook Choi
    BMC Nephrology, 20
  • [32] microRNA-21 inhibition prevents adverse cardiac remodeling and dysfunction following myocardial infarction, an effect driven by macrophages
    Fernandez, I. Duran
    Ramanujam, D. P.
    Beck, C.
    Vaccarello, P.
    Engelhardt, S.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 : S3 - S3
  • [33] PMCA4 inhibition does not affect cardiac remodelling following myocardial infarction, but may reduce susceptibility to arrhythmia
    Nicholas Stafford
    Min Zi
    Florence Baudoin
    Tamer M. A. Mohamed
    Sukhpal Prehar
    Daria De Giorgio
    Elizabeth J. Cartwright
    Roberto Latini
    Ludwig Neyses
    Delvac Oceandy
    Scientific Reports, 11
  • [34] PMCA4 inhibition does not affect cardiac remodelling following myocardial infarction, but may reduce susceptibility to arrhythmia
    Stafford, Nicholas
    Zi, Min
    Baudoin, Florence
    Mohamed, Tamer M. A.
    Prehar, Sukhpal
    De Giorgio, Daria
    Cartwright, Elizabeth J.
    Latini, Roberto
    Neyses, Ludwig
    Oceandy, Delvac
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [35] Novel combination treatment of type 2 diabetes DPP-4 inhibition
    Ahren, Bo
    VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (02) : 383 - 394
  • [36] Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKC/Gal-3 signaling pathway attenuates adverse cardiac fibrosis, following myocardial infarction
    Del Carmen Asensio, M. C. Maria
    Lax, A.
    Fernandez Del Palacio, M. J.
    Sanchez Perez, M. C.
    Sassi, Y.
    Hajjar, R.
    Pascual Figal, D. A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 344 - 344
  • [37] Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKC/Gal-3 signaling pathway attenuates adverse cardiac fibrosis, following myocardial infarction
    Asensio Lopez, M. C.
    Lax, A. M.
    Sanchez Perez, M. T.
    Yassine, S.
    Hajjar, R.
    Pascual Figal, D. A.
    EUROPEAN HEART JOURNAL, 2018, 39 : 181 - 182
  • [38] DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome
    Yochai Birnbaum
    Dat Tran
    Mandeep Bajaj
    Yumei Ye
    Basic Research in Cardiology, 2019, 114
  • [39] DPP-4 INHIBITION BY LINAGLIPTIN PREVENTS CARDIAC DYSFUNCTION AND INFLAMMATION BY TARGETING THE NLRP3/ASC INFLAMMASOME
    Ye, Y.
    Bajaj, M.
    Birnbaum, Y.
    CARDIOLOGY, 2017, 137 : 106 - 106
  • [40] DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome
    Birnbaum, Yochai
    Tran, Dat
    Bajaj, Mandeep
    Ye, Yumei
    BASIC RESEARCH IN CARDIOLOGY, 2019, 114 (05)
12345